ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

On November 10, 2020 ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, reported that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET (Press release, ADC Therapeutics, NOV 10, 2020, View Source [SID1234570436]). A live webcast of the presentation will be available at View Source An archived version of the webcast will be available after the completion of the event at www.ir.adctherapeutics.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

On November 10, 2020 Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended September 30, 2020 (Press release, Adaptive Biotechnologies, NOV 10, 2020, View Source [SID1234570435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over the last quarter, we have demonstrated the unique capability of our platform to translate the immune response at scale into data that informs the development of best-in-class, differentiated diagnostic and therapeutic solutions," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This pandemic has highlighted the key role of the immune response in our understanding of disease. COVID-19 is a prime example of the power of our platform to rapidly generate immune-driven solutions to any disease, including what we believe are best-in-class antibodies against the virus."

Recent Highlights

Revenue was $26.3 million for the quarter ended September 30, 2020, representing a 25% increase from the second quarter 2020 and a 1% increase from the third quarter in the prior year.
Clinical sequencing volume increased 58% to 4,023 clinical tests delivered in the third quarter of 2020 compared to the third quarter 2019 and increased 28% compared to the second quarter 2020.
Identified two antibodies against SARS-CoV-2 that neutralize the virus at very low concentrations.
immunoSEQ T-MAP COVID to be used in a subset of patients from clinical trials of two top tier vaccine developers.
Top-line results from a second real-world study, conducted in Italy, demonstrated T-cell testing outperforms serology in identifying past SARS-CoV-2 infections (97% sensitivity versus 77%) supporting launch of T-Detect COVID, a clinical T-cell based test for past infection.
Identified clinical signal for Crohn’s disease for T-Detect pipeline.
Third Quarter 2020 Financial Results

Revenue was $26.3 million for the quarter ended September 30, 2020, representing a 1% increase from the third quarter in the prior year. Sequencing revenue was $11.3 million for the quarter, representing a 3% decrease from the third quarter in the prior year. Development revenue increased to $15.0 million for the quarter, representing a 5% increase from the third quarter in the prior year.

Operating expenses were $63.3 million for the third quarter of 2020, compared to $44.1 million in the third quarter of the prior year, representing an increase of 44%.

Net loss was $36.7 million for the third quarter of 2020, compared to $14.0 million for the same period in 2019.

Adjusted EBITDA (non-GAAP) was a loss of $28.4 million for the third quarter of 2020, compared to a loss of $12.7 million for the third quarter of the prior year.

Cash, cash equivalents and marketable securities was $851.5 million as of September 30, 2020.

2020 Financial Guidance

Adaptive Biotechnologies is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its third quarter financial results after market close on Tuesday, November 10, 2020 at 4:30 PM Eastern Time. The conference call can be accessed at View Source The webcast will be archived and available for replay at least 90 days after the event.

CNBG Sumgen Announces Clinical Trial Approval of SG404

On November 9, 2020, Sumgen Biotech reported that the IND application for its anti-CD47 product SG404 was approved by the Center for Drug Evaluation (CDE) of NMPA (Press release, Sumgen Biotech, NOV 9, 2020, View Source;a=nav&id=241 [SID1234625260]). This is the first clinical trial approval received by CNBG Sumgen since its founding in Mar. 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the past decade, the CD47-SIRPα signaling pathway has become a potential target for tumor immunotherapy. At the ASH (Free ASH Whitepaper) meeting held in Dec. last year, Forty Seven demonstrated that the combined use of its anti-CD47 antibody Magrolimab and Azacitidine resulted in an overall response rate (ORR) of up to 92% in previously untreated high-risk myelodysplastic syndrome (MDS) patients and up to 64% in untreated AML patients. These promising data brought great encouragement to other companies engaged in the development of anti-CD47 therapies. In Mar. 2020, pharmaceutical giant Gilead Sciences acquired Forty Seven for $4.9 billion USD.

According to the NextPharma database, there are currently over 50 anti-CD47 therapies under development worldwide, including nearly 20 candidate drugs in the clinical stage. Although there are many candidate drugs in the clinical trial, erythrotoxicity remains a topic of controversy in the developability of CD47. Therefore, further research is needed for the design of safer and more effective CD47-targeted drugs.

TaiGen Partners with GPCR to develop Burixafor & Taigexyn

On November 9th, 2020 TaiGen Biotechnology Company reported that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn (nemonoxacin) in South Korea (Press release, TaiGen Biotechnology, NOV 9, 2020, View Source [SID1234621604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantation and a chemosensitizer in hematological and solid tumors. It can also be used for stem cell collection in healthy individuals for personalized regenerative medicine. Taigexyn is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria.

Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea and Burixafor worldwide. Apart from upfront fees, TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments.

GPCR Therapeutics is a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is a well-accepted avenue towards cancer therapy and GPCR Therapeutics is well experienced and possesses the necessary know-how to develop Burixafor in the oncology field.

Dongseung Seen, CEO of GPCR Therapeutics, said "This collaboration with TaiGen, which is a leading biotech company engaged in innovative molecular-based platforms with strong R&D capabilities, will lead to a long-term strategic and productive partnership. Further, it is our goal that our work together will position us to be a pre-eminent developer of anti-CXCR4 oncology drugs."

Kuo-Lung Huang, Chairman and Chief Executive Officer of Licensor, said, "This agreement and collaboration with GPCR is a tremendous progress in the continued development of Burixafor. Through the collaboration with GPCR Therapeutics, a novel and effective treatment for cancer patients possessing CXCR4 heteromers is on the horizon while a highly effective antibiotic will enter the S. Korea market to address their unmet medical needs in the near future"

About Burixafor

A stem cell mobilizer, Burixafor, is TaiGen’s first fully in-house developed product, a First-in-Class drug with an IND under US FDA. With a variety of potential applications in a number of disease indications, if proven effective in clinical trials, Burixafor will be able to address several unmet medical needs. The molecule is a potent and selective chemokine receptor antagonist which can rapidly mobilize stem cells and progenitor cells from the bone marrow into peripheral circulation. Burixafor also has potential application in chemosensitization treatment of leukemia patients, delaying relapse after chemotherapy.

About Taigexyn

Taigexyn is a novel non-fluorinated quinolone available in both oral and intravenous formulations. The oral formulation of Taigexyn have received market approval in Taiwan and mainland China shown activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA as well as quinolone-resistant Streptococcus pneumonia. TaiGen partnered with Zhejiang Medicaine Co., Holding Distribution, R-Pharm of Russia, Productos Científicos S.A. de C.V., Luminarie Canada Inc. and GPCR Therapeutics, Inc. in 36 countries worldwide. In addition to the oral formulation, TaiGen granted NDA approval for intravenous formulation in Taiwan and is going to obtain the market approval in mainland China.

Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary

On November 9, 2020 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, reported three poster presentations highlighting the Company’s clinical and pipeline progress at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 35th Anniversary Annual Meeting (SITC 2020) (Press release, Cue Biopharma, NOV 9, 2020, View Source [SID1234608293]). The posters include a clinical update on CUE-101, the lead drug candidate from the IL-2 based CUE-100 series, and data supporting the potential of the Immuno-STAT (Selective Targeting and Alteration of T cells) platform to selectively engage and modulate targeted T cells within the body in a manner that can address a broad range of indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to share data providing further supportive evidence of the potential benefits of our Immuno-STAT platform throughout its stages of development," said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. "We are encouraged by the dose-proportional signals and metrics of clinical activity as well as the tolerability observed in our ongoing Phase 1 trial of CUE-101, as we continue enrollment with the next incremental level of dosing. Our preclinical data demonstrate the potential versatility and modularity of the Immuno-STAT platform for a wide array of indications, including the potential for prognostics and diagnostics, with evidence of localization and engagement with disease-relevant T cells, as well as activation and expansion."

Due to the abstract submission and acceptance dates for SITC (Free SITC Whitepaper), the poster highlighting progress on CUE-101 will only contain data updates through cohort 4. Members of the Cue Biopharma executive management team will provide further updates and details pertaining to patients from cohorts 4, 5 and 6 at the upcoming quarterly update call on November 17 at 4:30 p.m. EST. In addition, Cue Biopharma has recently received permission from the Clinical Safety and Review Committee to proceed with dose escalation to cohort 7 at 8 mg/kg.

The SITC (Free SITC Whitepaper) Presentations include:

A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer (Abstract #354)
Presenter: Sara I. Pai, M.D., Ph.D., associate professor, Massachusetts General Hospital and Harvard Medical School, Boston

An ongoing multicenter, open-label, dose escalation Phase 1 trial is evaluating the safety, tolerability, anti-tumor response, pharmacokinetics and immunogenicity of CUE-101 as a monotherapy in patients with confirmed human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ HNSCC) and HLA-A*02:01 serotype (NCT03978689). Results from 19 participants who have received CUE-101 at doses ranging from 0.06 to 1 mg/kg demonstrate acceptable tolerability, favorable pharmacokinetics (PK) and preliminary pharmacodynamics (PD) signals that indicate selective activation of tumor-specific T cells, enabling dose escalation to the next level (2 mg/kg).

CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells (Abstract #553)
Presenter: Saso Cemerski, Ph.D., ‎vice president and head, discovery and translational immunology, Cue Biopharma

In vitro and in vivo evaluation of CUE-100 series Immuno-STATs specific to different antigenic peptides demonstrated expansion of functional, oligoclonal, antigen-specific T cell repertoires with functional attenuation of the IL-2 components. CUE-100 series Immuno-STATs administered to human peripheral blood mononuclear cells (PBMCs) selectively activated and expanded antigen-specific CD8+ T cells after primary stimulation and re-stimulation with antigenic peptides from HPV16, Wilms’ tumor 1 (WT1), melanoma antigen recognized by T cells 1 (MART-1), cytomegalovirus (CMV), influenza and HIV. In naïve HLA-A*02 transgenic mice, CUE-100 series Immuno-STATs expanded CD8+ T cells, exhibiting a polyfunctional response upon challenge with peptide-presenting target cells.

Immuno-STATs: Leveraging protein engineering to expand and track antigen-specific T cells in vivo (Abstract #623)
Presenter: Steven Almo, Ph.D., ‎co-founder, Cue Biopharma

The potential modularity of the Immuno-STAT platform and ability to selectively deliver costimulatory, coinhibitory or cytokine signals and other modalities to primary T cells of defined specificity was observed through the use of a novel immuno-positron emission tomography (PET) imaging approach. PET-active radiolabels were installed on dimeric protein scaffolds comprising the core structure of the Immuno-STAT to visualize the in vivo localization of antigen-specific T cells. Results showed that HPV16-specific CD8+ T cells were localized to implanted HPV16-positive tumors in mice, and influenza A virus (IAV)-specific CD8+ T cells were localized to the lungs of IAV-infected mice. HIV- and CMV-specific Immuno-STATs administered to immunodeficient mice intrasplenically engrafted with human PBMCs resulted in selective expansion of disease-relevant T cells in the spleen. These data represent the first report of the in vivo imaging of antigen-specific CD8+ T cell populations and in vivo antigen-selective expansion of human CD8+ T cells, which suggests the presence of Immuno-STAT biologics in the particular tumor or infected tissues where they act, eliciting selective activation and expansion of target T cells. These results suggest that, in addition to broad therapeutic applications, Immuno-STATs may also provide prognostic and diagnostic information.

For more information on all three posters please visit: https://bit.ly/3k4HymQ.

About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About Immuno-STAT
Immuno-STAT biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.